GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » Gross Margin %
中文

Invitae (Invitae) Gross Margin % : 32.21% (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Invitae Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Invitae's Gross Profit for the three months ended in Sep. 2023 was $39.1 Mil. Invitae's Revenue for the three months ended in Sep. 2023 was $121.2 Mil. Therefore, Invitae's Gross Margin % for the quarter that ended in Sep. 2023 was 32.21%.

Warning Sign:

Invitae Corp gross margin has been in long-term decline. The average rate of decline per year is -10.7%.


The historical rank and industry rank for Invitae's Gross Margin % or its related term are showing as below:

NVTAQ' s Gross Margin % Range Over the Past 10 Years
Min: -350.68   Med: 21.73   Max: 45.76
Current: 27.13


During the past 11 years, the highest Gross Margin % of Invitae was 45.76%. The lowest was -350.68%. And the median was 21.73%.

NVTAQ's Gross Margin % is ranked worse than
81.94% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 45.595 vs NVTAQ: 27.13

Invitae had a gross margin of 32.21% for the quarter that ended in Sep. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Invitae was -10.70% per year.


Invitae Gross Margin % Historical Data

The historical data trend for Invitae's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae Gross Margin % Chart

Invitae Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.76 45.53 29.09 24.28 19.18

Invitae Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.42 24.18 24.64 27.43 32.21

Competitive Comparison of Invitae's Gross Margin %

For the Diagnostics & Research subindustry, Invitae's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invitae's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invitae's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Invitae's Gross Margin % falls into.



Invitae Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Invitae's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=99 / 516.303
=(Revenue - Cost of Goods Sold) / Revenue
=(516.303 - 417.256) / 516.303
=19.18 %

Invitae's Gross Margin for the quarter that ended in Sep. 2023 is calculated as


Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=39.1 / 121.241
=(Revenue - Cost of Goods Sold) / Revenue
=(121.241 - 82.186) / 121.241
=32.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Invitae  (OTCPK:NVTAQ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Invitae had a gross margin of 32.21% for the quarter that ended in Sep. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Invitae Gross Margin % Related Terms

Thank you for viewing the detailed overview of Invitae's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Invitae (Invitae) Business Description

Traded in Other Exchanges
Address
1400 16th Street, San Francisco, CA, USA, 94103
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
Executives
Ana J. Schrank officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley officer: Chief Commercial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey officer: See Remarks 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons officer: See remarks 2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum officer: Chief Medical Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida officer: General Counsel 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight officer: Chief Operating Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne director 1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George director, officer: CEO 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer officer: Chief Financial Officer 1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland officer: Chief Commercial Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse director 3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers director, other: President, Oncology C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301

Invitae (Invitae) Headlines

From GuruFocus

Q4 2019 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2023 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Invitae Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 02-14-2024

Q2 2021 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2020 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2020 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024